Who
Matthew Ros
Director
Company insider
Files Form 4 as: Director, Cogent Biosciences; Chief Operating Officer, Verastem; Chief Operating Officer, Epizyme.
In numbers
- Trades disclosed
- 65
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $3.7M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 16 May 2016
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,700 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Jun 2024filed 13 Jun 2024 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,700 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,051 at $0.00 | filing |
| 2 Oct 2023filed 3 Oct 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,170 at $0.00 | filing |
| 3 Jul 2023filed 5 Jul 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,743 at $0.00 | filing |
| 7 Jun 2023filed 8 Jun 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,700 at $0.00 | filing |
| 3 Apr 2023filed 4 Apr 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,900 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $13K1,792 at $7.19 | filing |
| 3 Oct 2022filed 4 Oct 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $13K1,419 at $9.08 | filing |
| 1 Jul 2022filed 5 Jul 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $13K2,194 at $5.87 | filing |
| 7 Jun 2022filed 9 Jun 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 1 Apr 2022filed 5 Apr 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $13K2,650 at $4.86 | filing |
| 3 Jan 2022filed 4 Jan 2022 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $12K2,256 at $5.15 | filing |
| 1 Oct 2021filed 5 Oct 2021 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $12K2,463 at $5.03 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Epizymeoption or derivative | SEC FORM 4 Code A | —134,178 at $0.00 | filing |
| 16 Aug 2021filed 18 Aug 2021 | Epizyme | SEC FORM 4 Code A | —28,125 at $0.00 | filing |
| 1 Jul 2021filed 6 Jul 2021 | COGT Cogent Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K2,225 at $4.78 | filing |
News
No headline names them, or the companies they trade most, lately.